MPP合并心肌损伤的危险因素及益生菌辅助治疗的临床效果分析

Resk factors of MPP combined with myocardial injury and clinical effect analysis of probiotic-assisted therapy

目的 探讨MPP(肺炎支原体肺炎)合并心肌损伤的危险因素及益生菌辅助治疗的效果。方法 本次对象为我院MPP合并心肌损伤患儿116例,取至2021年4月—2023年4月,随机分为研究组、对照组,每组有患儿58例。对照组采用阿奇霉素治疗,研究组采用阿奇霉素+益生菌治疗,评定不同组别的治疗效果,并总结危险因素。结果 经调查,MPP合并心肌损伤的危险因素有患儿发热>5d、发病年龄<2岁、WBC异常、胸部提示大叶性肺炎、阵发性痉挛性咳嗽。研究组治疗好转率为96.55%,略高于对照组的81.03%(P<0.05)。治疗1个月后,研究组CRP、TNF-α、IL-1水平略低于对照组(P<0.05)。治疗1个月后,研究组LVEF水平略高于对照组,LVESVI、LVEDVI水平略低于对照组(P<0.05)。结论 发热>5d、发病年龄<2岁、WBC异常、胸部提示大叶性肺炎、阵发性痉挛性咳嗽为MPP合并心肌损伤的危险因素,临床应加强管理,完善心脏彩超、心电图等检查,并积极采用阿奇霉素、益生菌联合治疗,以便改善患儿症状和心功能,降低炎性因子水平,增强临床疗效。

Objective To investigate the risk factors of MPP(Mycoplasma pneumoniae pneumonia) combined with myocardial injury and the effect of probiotic adjuvant therapy. Methods The subjects were one hundred and sixteen cases of children with MPP combined with myocardial injury in our hospital, taken until April 2021-April 2023,randomly divided into study group and control group, with 58 cases in each group.The control group was treated with azithromycin and the study group was treated with azithromycin + probiotics to evaluate the treatment effect of different groups and to summarize the risk factors. Results After investigation, the risk factors for MPP combined with myocardial injury include fever>5 days, onset age<2 years, abnormal WBC,chest suggestive lobar pneumonia, and paroxysmal spasmodic cough in the child.The improvement rate of treatment in the study group was 96.55%,slightly higher than 81.03% in the control group(P<0.05).After 1 month of treatment, the CRP,TNF-α,and IL-1 levels in the study group were slightly lower than those in the control group(P<0.05).4) After 1 month of treatment, LVEF levels in the study group were slightly higher than those in the control group, and LVESVI and LVEDVI levels were slightly lower than those in the control group(P<0.05). Conclusion Fever>5 days, onset age<2 years, abnormal WBC,lobar pneumonia in the chest, paroxysmal spastic cough are the risk factors for MPP with myocardial injury.Clinical management should be strengthened, cardiac color ultrasound, electrocardiogram and other examinations should be improved, and Azithromycin and probiotics should be actively combined to improve the symptoms and cardiac function of children, reduce the level of inflammatory factors, and enhance clinical efficacy.